To start your customized experience click the start button
Customize ?  
Cancer Types
Quick Links
Award Programs
About Us
Contact Us
Privacy Policy
Terms & Conditions
Face Book
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2018
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.


Brielle Urciuoli
A new drug combination bested current standard of care in a clinical trial.
Jason M. Broderick
The Food and Drug Administration (FDA) granted duvelisib a priority review to a new drug application (NDA) for full approval to treat patients who have relapsed or refractory chronic lymphocytic leukemia or small lymphocytic leukemia (CLL/SLL). The FDA also granted an accelerated approval for the treatment of patients with relapsed or refractory follicular lymphoma.
Brian Koffman, MDCM, MSEd, provides insight from a patient’s perspective on self-advocacy and reflects on the positive direction in which the treatment paradigm of chronic lymphocytic leukemia (CLL) is heading.
Brian Koffman, MDCM, MSEd, describes the inspiration he had to form the nonprofit CLL Society and outlines the resources it provides for any patient with chronic lymphocytic leukemia (CLL).
Brian Koffman, MDCM, MSEd, shares insight on his current relapse of chronic lymphocytic leukemia (CLL) and discusses the potential value of chimeric antigen receptor (CAR) T-cell therapy, which he will be receiving in an upcoming clinical trial.
Brian Koffman, MDCM, MSEd, discusses his rejection of allogeneic stem cell transplant and development of chemorefractory chronic lymphocytic leukemia (CLL) that led to his participation in an early clinical trial of ibrutinib.
Brian Koffman, MDCM, MSEd, describes his own case of chronic lymphocytic leukemia and idiopathic thrombocytopenic purpura (ITP), identifying the symptoms he experienced before and after his diagnosis.
Katie Kosko
Survey finds quality of life and cost affect treatment decisions.
William G. Wierda, M.D., Ph.D.
William G. Wierda, M.D., Ph.D., medical director of the Leukemia Center at The University of Texas MD Anderson Cancer Center, discusses how to best combine and sequence therapies for patients with chronic lymphocytic leukemia (CLL).
Nicole Lamanna, MD, reminds patients with chronic lymphocytic leukemia about current research efforts and new therapies that are helping to transform how CLL is managed. Additionally, Dr. Lamanna offers advice to newly diagnosed patients.

Sign In

Not a member? Sign up now!
Continue without login

Sign Up

In Treatment

Maintenance/Hormone Treatment

Out of Treatment


Healthcare Professional

Not Applicable